{"id":135899,"title":"Avacta strengthens cancer treatment story with clinical advances","publisher":"Share Talk","author":"sharetalk","published":"2026-05-19T06:24:05+00:00","modified":"2026-05-19T06:24:05+00:00","canonical_url":"https://www.share-talk.com/avacta-strengthens-cancer-treatment-story-with-clinical-advances/","markdown_url":"https://www.share-talk.com/avacta-strengthens-cancer-treatment-story-with-clinical-advances.md","json_url":"https://www.share-talk.com/avacta-strengthens-cancer-treatment-story-with-clinical-advances.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Abingdon Health","AffyXell Therapeutics","antigen","Avacta Group","AVCT","Biotherapeutics","Chris Yates","Christina Coughlin","clinical","COVID-19","Cytiva","Daewoong Pharmaceutical","diagnostic","Doncaster","Europe","LG Chem Life Sciences","Michelle Morrow","Pharma","radiopharmaceuticals","saliva test","SARS-COV-2","Sengho Jeon","Share Talk","South Korea","therapeutic","UK","validation","York"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/03/AVCT-7-MARCH.webp?fit=1200%2C800&quality=80&ssl=1","format":"news","language":"en-GB","content":"[Avacta Group plc](https://www.investegate.co.uk/announcement/rns/avacta-group--avct/unaudited-preliminary-full-year-2025-results-/9574278) has reported significant progress across its pre|CISION oncology platform in its unaudited preliminary results for the year ended December 31, 2025, as the company advances multiple cancer therapies through clinical development.\n\nThe biotechnology group said it now has two programmes in clinical trials, including continued progress with AVA6000 and the advancement of AVA6103 into Phase 1 patient treatment.\n\nAvacta highlighted encouraging efficacy and safety data from AVA6000, which forms part of the company’s tumour-targeted chemotherapy platform designed to reduce systemic toxicity while improving drug delivery directly to cancer tissue.\n\nFinancially, the company strengthened its balance sheet through multiple fundraisings, securing £22.5 million in new equity during 2025 followed by an additional £10 million financing completed in March 2026.\n\nManagement said the funding extends the group’s cash runway into the first quarter of 2027.\n\nAt the end of 2025, Avacta held cash and short-term deposits of £16.9 million.\n\nThe group reported a loss before tax from continuing operations of £36.84 million for the year, compared with a loss of £28.98 million in the previous year, reflecting continued investment into clinical development and research activities.\n\nAvacta also confirmed completion of the disposal of its diagnostics businesses, marking a further step in its transition towards becoming a focused oncology therapeutics company.\n\nChristina Coughlin said Avacta Group plc has made significant progress in strengthening its position as a focused oncology therapeutics business centred around its proprietary pre|CISION platform.\n\nCoughlin highlighted that the company already has two programmes in clinical development, which she described as ahead of the industry norm for companies at a similar stage.\n\nShe said Avacta believes its pre|CISION technology offers a unique advantage by enabling cancer therapies to be delivered directly to tumours at effective concentrations while avoiding the severe toxic side effects often associated with conventional chemotherapy treatments.\n\nThe CEO also pointed to the company’s expanding intellectual property portfolio, which she said is attracting increasing interest from multiple parties regarding potential commercial partnerships and licensing opportunities.\n\nAccording to Coughlin, these agreements could both generate future revenue and expand the potential applications of the company’s technology platform.\n\nShe added that Avacta’s financial position has been significantly strengthened following £32.5 million of fundraising over the past 18 months, providing sufficient funding into early Q1 2027 and through several anticipated clinical and commercial milestones.\n\nCoughlin described the coming period as potentially transformative both for the company and for patients targeted by its oncology pipeline.\n\nFor further information from Avacta, please contact:\n\n|   |   |\n| --- | --- |\n| Avacta Group plc Christina Coughlin, Chief Executive Officer | [https://avacta.com/](https://avacta.com/) via Cohesion Bureau |"}